Geistlich expands its range of technologies and ventures into new markets

Diego Gabathuler, CEO at Geistlich, says: «Our high-tech biomaterials have made a significant contribution to the positive development of the implant market. With our new technologies, we will continue to spur this development.»

Geistlich stands for quality-oriented medical regeneration. This is crucial for good health and a high quality of life. In the coming months, Geistlich intends to expand the range of its regenerative products through in-house developments, acquisitions, and partnerships. To this end, Geistlich will tailor its solutions more specifically for specialists, dental service organizations (DSOs), general dentists, and emerging markets. In this way, by 2035, Geistlich aspires to improve the quality of life of over 80 million people through dental regeneration. «Next year, Geistlich is celebrating its 175th anniversary. Our well-filled pipeline marks another milestone in the company’s history by adding new technologies, new brands, and new channels. », adds Diego Gabathuler.

Trusted Geistlich technology in new handling variants
At the annual meeting of the American Academy of Periodontology (AAP) in Toronto, Geistlich has presented Geistlich Bio-Gide® Forte to the professional community for the first time. This new collagen membrane for reliable bone regeneration and tissue integration is particularly firm and stable in consistency when hydrated. The membrane unfolds effortlessly, adapts flexibly to the defect, and can even be cut when hydrated. In 2026, the Swiss Company will launch its Geistlich Bio-Oss® in a flowable form containing 80% Geistlich Bio-Oss® and 20% Geistlich Bio-Gide® collagen. The application is very fast through a bendable cannula.

Closing gaps with quality-based solutions in Emerging Markets
In the past two years, Geistlich has enriched its own regenerative solutions with latest technologies through acquisitions and strategic investments. These include Lynch Biologics, LLC with GEM 21S®, a growth factor–based product, allografts from O.S.T, or ReOss, which is well-known for its patient-specific solutions that incorporate digital patient data with 3D-printing technology. With Bionnovation Biomedical Geistlich has started to expand in Emerging Markets with reliable, affordable solutions. This strategy is now being accelerated with in-house-developed products named Geistlich SwissGraft® X and Geistlich SwissMembrane® X, which are cost-efficient and specially developed solutions for daily practical use. The products combine proven Swiss quality with ease of use. The launch will begin in selected markets where the demand for accessible biomaterials is particularly high.